TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.85
-0.20 (-1.42%)
Jan 22, 2026, 11:19 AM CST
28.24%
Market Cap10.00B
Revenue (ttm)38.75M
Net Income (ttm)-184.20M
Shares Out711.83M
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,064,609
Average Volume6,587,138
Open14.20
Previous Close14.05
Day's Range13.80 - 14.25
52-Week Range7.44 - 16.40
Beta0.25
RSI57.19
Earnings DateMar 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements